Ligand id: 1135

Name: exendin-4

No information available.
Summary of Clinical Use
Approved to treat type 2 diabetes mellitus (T2DM) in patients whose blood sugar is inadequately controlled by other antidiabetes medicines (e.g. metformin, sulphonylureas, thiazolidinediones) or basal insulin. An extended-release formulation for once-weekly administration by injection (called Bydureon® BCiseTM) was FDA approved in October 2017, and as of April 2018 can be used as an adjunct to basal insulin therapy in adults with (T2DM), with or without metformin.
Mechanism Of Action and Pharmacodynamic Effects
Acts as a GLP-1 receptor agonist and mimics the action of endogenous GLP-1 peptide in controlling blood sugar levels via improved insulin and glucagon secretion and decreased food intake.
External links